Efficacy and rapid activity of omalizumab retreatment in chronic spontaneous urticaria

J Am Acad Dermatol. 2018 Jun;78(6):1211-1213. doi: 10.1016/j.jaad.2017.11.047. Epub 2017 Dec 5.
No abstract available

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Chronic Disease
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Omalizumab / therapeutic use*
  • Prognosis
  • Recurrence
  • Retreatment
  • Retrospective Studies
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome
  • Urticaria / diagnosis*
  • Urticaria / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Omalizumab